Treatment Comparison Chart

Comparison Chart

Back to Treatment Guide
Please note: this tool only compares prescription information and is not meant to compare effectiveness of medications.
Chemical Name
Interferon beta-1a
monomethyl fumarate
When was this therapy FDA approved?
How do I take the therapy?
How often do I take the therapy?
Once per day.
Half-dose (95 mgs) taken twice daily for the first 7 days; then full maintenance dose (190 mgs) taken twice daily.
What type of MS is this treatment FDA approved for?
  • Relapsing-remitting MS
  • Secondary-progressive MS
  • Clinically Isolated Syndrome
  • Relapsing remitting MS
  • Secondary progressive MS
  • Clinically Isolated Syndrome
  • Relapsing-remitting MS
  • Secondary-progressive MS
  • Clinically Isolated Syndrome
Side effects (disclaimer: speak to your healthcare provider about serious and/or rare side effects)
  • Increase in liver enzymes
  • Nausea and diarrhea
  • Hair thinning
  • Flu-like symptoms
  • Upper respiratory infection
  • White blood count and liver test abnormalities
  • Flushing and stomach problems, especially at the start of therapy, and may decrease over time
  • Redness, itching, rash
  • Diarrhea
How often do I need to visit my healthcare provider for regular monitoring and tests?
TB test and liver function blood test within 6 months before starting Aubagio. Liver function must be checked monthly for the first 6 months of treatment.
Recommend follow-up visits intervals of every 6 months at a minimum with your healthcare provider.
Every 6 to 12 months or as directed by your HCP.

Those testing positive for tuberculosis.

Those with a hypersensitivity to natural or recombinant interferon beta.

Those currently taking dimethyl fumarate or diroximel fumarate and those with hypersensitivity to monomethyl fumarate, dimethyl fumarate, diroximel fumarate.

Conception and pregnancy

Both men and women risk fetal harm if taking Aubagio®.

Potential for fetal harm unknown.

No established risk to fetus.